Jeffrey D. Osterman
Biography

Jeffrey regularly advises major pharmaceutical companies in connection with licensing and collaboration agreements; represents semiconductor and other technology companies in connection with development and licensing agreements; leads the technology and intellectual property aspects of major corporate transactions; and advises on the treatment of intellectual property matters in bankruptcy cases.
Jeffrey lived in Japan from May 1997 to May 1998 where he worked in-house on loan to the headquarters of Panasonic Corporation.
Jeffrey is ranked Band 1 for Technology & Outsourcing in New York by Chambers USA, where clients note “he’s one of the top lawyers in this space, a very knowledgeable and impressive individual.” "He’s just extremely thorough and he has the memory of an elephant." He is also recommended for Technology Transactions and Healthcare: Life Sciences by Legal 500 US. Jeffrey is recognized as an “IP Star” for IP Transactions and Trademarks by Managing Intellectual Property, as a Financial & Corporate Life Science Star by LMG Life Sciences Guide and has been named 2020 “Lawyer of the Year” for Technology Law in New York by Best Lawyers in America. He is named a “Global Leader” in New York by IAM Global Leaders and is “Highly Recommended” by IAM Patent 1000, where clients have noted he has “a stellar ability to see the forest through the trees, is a clear and concise draftsman and a constructive negotiator,” and that he is “the kind of sophisticated IP lawyer you need on a tough deal – he understands his clients’ industry and business, and fights hard while communicating clearly in negotiations to get to a resolution.” Jeffrey was named a 2016 Technology “MVP” by Law360.
Awards and Recognition, Speaking Engagements, Guides and Resources, Firm News & Announcements
Awards and Recognition
- Jeffrey Osterman Ranked Band 1 for Technology & Outsourcing in New York Award Brief — Chambers USA
- Jeffery Osterman Named 2020 “Lawyer of the Year” for Technology Law in New York Award Brief — Best Lawyers in America
- Jeffrey Osterman Named an "IP Star" for IP Transactions and Trademarks in New York Award Brief — Managing Intellectual Property IP Stars
- Jeffrey Osterman Named a Financial & Corporate Life Science Star Award Brief — LMG Life Sciences Guide
- Jeffrey Osterman Named a “Global Leader” in New York Award Brief — IAM Patent 1000 Global Leaders Guide
- Jeffrey Osterman “Highly Recommended” for Transactions in New York Award Brief — IAM Patent 1000
- Jeffrey Osterman Recommended for Technology Transactions Award Brief — Legal 500 US
Speaking Engagements
-
PLI’s IP Issues in Business Transactions 2021
Speaker(s):
Jeffrey D. Osterman
February 5, 2021 — Weil Technology & IP Transactions partner Jeffrey Osterman spoke on a panel titled “Bankruptcy Issues in IP Transactions” as part of PLI’s IP Issues in Business Transactions 2021.
-
PLI’s Understanding the Intellectual Property License 2020
Speaker(s):
Jeffrey D. Osterman
November 5, 2020 — New York, NY — Weil Technology & IP Transactions partner Jeffrey Osterman spoke on “Software Licensing,” as part of PLI’s Understanding the Intellectual Property License 2020. The presentation covered source code versus object code licenses; representations, warranties, indemnities and audit rights; key open source licensing concepts and terms; and license and open source compliance strategies.
Firm News & Announcements
- Weil Advises Poppulo in its Merger with Four Winds Interactive LLC Deal Brief — March 15, 2021
- Weil Advised GI Partners in its Acquisition of Vast Broadband Firm Announcement — February 01, 2021
- Weil Advised American Securities in its $1.37B Take-Private of Foundation Building Materials Firm Announcement — January 21, 2021
- Weil Advised Advent International Corporation in its Stake Acquisition of RxBenefits, Inc. Deal Brief — January 19, 2021
- Weil Advised Eli Lilly in its $1 Billion Acquisition of Prevail Therapeutics Deal Brief — January 12, 2021
- Weil Advises Magellan Health in its $2.2B Merger with Centene Corporation Deal Brief — January 04, 2021